Physician

Ananea Adamidis, M.D.

According to 2025 Medicare claims, Ananea Adamidis, M.D. (NPI: 1235139957) practices nephrology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is EXCELCARE MEDICAL ASSOCIATES, PA (NPI: 1992736300; TIN: 203130405) and primary practice location at 07666-4245. Adamidis is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Adamidis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 446 traditional Medicare patients, billed 1,576 HCPCS/CPT codes, and received $154,999 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,601 prescription claims across 264 beneficiaries totaling $388,095 in drug costs, led by Rayaldee (Calcifediol). 2023 DME data shows 12 claims. Open Payments data shows 28 records totaling $493. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $277,816 and ending at $388,095. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	487	4,533	$175,670
2016	482	3,087	$182,300
2017	489	3,730	$190,488
2018	499	3,924	$186,655
2019	488	3,612	$215,980
2020	400	3,095	$174,968
2021	373	2,030	$169,771
2022	371	2,051	$146,636
2023	364	1,750	$144,312
2024	446	1,576	$154,999

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	147	1,047	$277,816
2016	157	1,065	$301,476
2017	159	1,039	$234,699
2018	164	1,043	$149,827
2019	192	1,248	$347,657
2020	177	1,141	$347,868
2021	203	1,231	$287,834
2022	216	1,334	$218,211
2023	239	1,500	$300,633
2024	264	1,601	$388,095

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$705
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$150
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	55	57	$149
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	44	47	$114
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	81	113	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	163	408	$74
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	145	321	$69

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rayaldee	Calcifediol	85	2,610	$109,555
Farxiga	Dapagliflozin Propanediol	41	3,030	$55,768
Jardiance	Empagliflozin	30	2,340	$44,060
Velphoro	Sucroferric Oxyhydroxide	20	718	$43,731
Veltassa	Patiromer Calcium Sorbitex	27	1,594	$38,917

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	28	$493	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ananea Adamidis, M.D.?

Tedicare shows public-source Medicare data for Ananea Adamidis, M.D. (NPI 1235139957), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ananea Adamidis, M.D. have ACO affiliation data?

Ananea Adamidis, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Ananea Adamidis, M.D.?

Ananea Adamidis, M.D. is linked to EXCELCARE MEDICAL ASSOCIATES, PA (billing NPI 1992736300) in the available physician profile data.

Does Ananea Adamidis, M.D. have Open Payments data?

Ananea Adamidis, M.D. has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.